Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms by Mowat, Craig et al.
                                                              
University of Dundee
Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients
presenting to primary care with bowel symptoms
Mowat, Craig; Digby, Jayne; Strachan, Judith A.; Wilson, Robyn; Carey, Francis A.; Fraser,
Callum G/; Steele, Robert
Published in:
Gut
DOI:
10.1136/gutjnl-2015-309579
Publication date:
2015
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Mowat, C., Digby, J., Strachan, J. A., Wilson, R., Carey, F. A., Fraser, C. G., & Steele, R. J. C. (2015). Faecal
haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with
bowel symptoms. Gut. 10.1136/gutjnl-2015-309579
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
ORIGINAL ARTICLE
Faecal haemoglobin and faecal calprotectin as
indicators of bowel disease in patients presenting
to primary care with bowel symptoms
Craig Mowat,1 Jayne Digby,2 Judith A Strachan,3 Robyn Wilson,3 Francis A Carey,4
Callum G Fraser,2 Robert J C Steele2
1Department of
Gastroenterology, Ninewells
Hospital & Medical School,
Dundee, UK
2Centre for Research into
cancer Prevention and
Screening
3Department of Blood
Sciences, Ninewells Hospital &
Medical School, Dundee, UK
4Department of Pathology,
Ninewells Hospital & Medical
School, Dundee, UK
Correspondence to
Dr Craig Mowat, Department
of Gastroenterology, Ninewells
Hospital & Medical School,
Dundee DD1 9SY, UK;
craig.mowat@nhs.net
Received 12 March 2015
Revised 4 June 2015
Accepted 6 June 2015
To cite: Mowat C, Digby J,
Strachan JA, et al. Gut
Published Online First:
[please include Day Month
Year] doi:10.1136/gutjnl-
2015-309579
ABSTRACT
Objective In primary care, assessing which patients
with bowel symptoms harbour significant disease
(cancer, higher-risk adenoma or IBD) is difficult. We
studied the diagnostic accuracies of faecal haemoglobin
(FHb) and faecal calprotectin (FC) in a cohort of
symptomatic patients.
Design From October 2013 to March 2014, general
practitioners were prompted to request FHb and FC
when referring patients with bowel symptoms to
secondary care. Faecal samples were analysed for
haemoglobin (EIKEN OC-Sensor io) and calprotectin
(BÜHLMANN Calprotectin ELISA). Patients triaged to
endoscopy were investigated within 6 weeks. All
clinicians and endoscopists were blind to the faecal test
results. The diagnostic accuracies of FHb and FC for
identification of significant bowel disease were assessed.
Results 1043 patients returned samples. FHb was
detectable in 57.6% (median 0.4 mg/g, 95% CI 0.4 to
0.8; range 0–200). FC at 50 mg/g or above was present
in 60.0%. 755 patients (54.6% women, median age
64 years (range 16–90, IQR 52–73)) returned samples
and completed colonic investigations. 103 patients had
significant bowel disease; the negative predictive values
of FHb for colorectal cancer, higher-risk adenoma and
IBD were 100%, 97.8% and 98.4%, respectively. Using
cut-offs of detectable FHb and/or 200 mg/g FC detected
two further cases of IBD, one higher-risk adenoma and
no additional cancers.
Conclusions In primary care, undetectable FHb is a
good ‘rule-out’ test for significant bowel disease and
could guide who requires investigation.
INTRODUCTION
Patients presenting to general practitioners (GPs)
describing new bowel symptoms can be difficult to
assess. Referral guidelines from the National
Institute for Health and Care Excellence (NICE)
highlight features that may suggest serious path-
ology.1 These include rectal bleeding, a mass on
examination, iron deficiency anaemia, but also non-
specific symptoms such as a persistent change in
bowel habit. The latest revision (due for publication
in June 2015) concedes that symptoms have a posi-
tive predictive value (PPV) for colorectal cancer
(CRC) of only 3–4%.2 A detailed review and
meta-analysis also concluded that symptoms alone
are poor predictors of underlying pathology.3 In the
absence of any reliable predictor of pathology,
patients will continue to be referred to secondary
care for investigation. Colonoscopy is the gold
standard for detection of significant bowel disease;
namely CRC, higher-risk adenoma (HRA, defined
as ≥three adenomas or any adenoma ≥1 cm)4 and
IBD. Low-risk adenomas (<1 cm) harbour a very
low risk of CRC and are excluded from this
category.5
Our health care system serves a population of
around 400 000. Each year approximately 4000
patients are referred from primary care for
Significance of this study
What is already known on this subject?
▸ Faecal haemoglobin (FHb) concentrations rise as
the severity of underlying neoplasia increases.
▸ Faecal immunochemical tests (FIT) for
haemoglobin have superseded guaiac faecal
occult blood tests (gFOBT) as the recommended
initial test in bowel cancer screening programmes.
▸ Faecal calprotectin (FC) concentrations rise with
inflammation and are useful for monitoring IBD
in secondary care.
▸ To date, no studies have examined the utility of
simultaneous quantitative estimates of FHb and
FC exclusively in primary care at the point of
referral.
What are the new findings?
▸ FHb and FC can be measured from a single
sample of faeces collected at home.
▸ Undetectable FHb measured in samples
collected in primary care proved a good
‘rule-out test’ for significant bowel disease;
cancer was excluded, and higher-risk adenomas
and IBD were rare.
▸ FC at <50 mg/g ruled out IBD but missed
cancer and adenomas.
How might it impact on clinical practice in
the foreseeable future?
▸ We have shown that FHb, measured with
quantitative FIT, can be used in primary care at
the point of referral as a reliable and objective
predictor of underlying pathology.
▸ General practitioners have an objective tool to
guide who requires further investigation in
secondary care.
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assessment of bowel symptoms via a dedicated referral portal,
ensuring equity of access and a streamlined booking process.
Referrals are triaged by consultant gastroenterologists; 75% are
brought straight to investigation and the remainder seen in out-
patient clinics. The percentage of referrals from GPs marked as
‘urgent’ or ‘urgent suspected cancer’ consistently runs at 35–
40%. However, when patients undergo colonoscopy, the yield
of significant bowel disease is low, with local audit revealing
CRC in only 2% and IBD in 5%.
New means of assessing patients in primary care are urgently
needed to help GPs determine which patients need rapid investi-
gation and, in turn, ease pressure on secondary care services.
Non-invasive faecal tests for blood and inflammation, already
established in CRC screening programmes and IBD clinics
respectively, may be helpful in this context.
Faecal immunochemical tests (FITs) for haemoglobin (Hb) are
specific for intact human Hb and its early degradation pro-
ducts.6 There are two types of FIT available: qualitative (based
upon immunochromatography and providing a positive or nega-
tive result) or quantitative (based upon latex agglutination
immunoturbidimetry and giving a numerical result for the faecal
Hb (FHb) concentration). Quantitative FITs have been recom-
mended over qualitative to remove reader variability, inter-batch
variability and to improve the diagnostic accuracy of the test.7 8
However, FITs made by different manufacturers are not identi-
cal.9 A range of FHb cut-off concentrations have been used for
CRC screening programmes (15–67 mg/g).10 Data from Europe
and Israel on quantitative FIT in patients under surveillance
suggest high specificity and negative predictive values (NPVs)
for CRC.11–13 Furthermore, a pilot study performed by our
group has suggested that low FHb may be a good rule-out test
for significant bowel disease in patients referred from primary
care.14
Faecal calprotectin (FC) has been measured in healthy
children and adults but is also a biomarker of inflammation; it
is stable at room temperature, homogeneously distributed
within faeces and correlates well with faecal excretion of
indium111-labelled neutrophil granulocytes—the gold standard
measure of gut inflammation.15 16 It can be analysed by qualita-
tive point-of-care immunochromatographic tests and quantita-
tive ELISA tests. Commonly available assays use a FC cut-off of
50 mg/g. FC has a role in the assessment of suspected IBD and
in the monitoring of patients with known IBD in secondary and
tertiary hospital clinics.15 17 NICE recommends that FC tests
should be available for GPs while acknowledging that further
research is required.18
In this study, our aim was to study the diagnostic accuracies of
quantitative FHb and FC tests in patients presenting to primary
care with bowel symptoms.
METHODS
This prospective study gained the full support of GPs and was
conducted following the STAndards for the Reporting of
Diagnostic accuracy studies guidelines.19 All adult patients
referred for investigation of bowel symptoms over a 6-month
period from October 2013 to March 2014 were eligible. At the
point of referring patients to the colorectal pathway, GPs were
prompted to request FHb and FC tests alongside full blood
count, urea and electrolytes and C reactive protein and record
the presenting symptoms via the NHS Tayside electronic test
requesting software. If patients had more than one presenting
symptom, for the purposes of the present analysis they were
attributed only one, in order of decreasing clinical importance
as follows: rectal bleeding, anaemia, diarrhoea, altered bowel
habit, abdominal pain and weight loss. The total number of
referrals and the urgency of the referral were recorded on the
referral management software. Practice nurses distributed an
EIKEN specimen collection device (for the FHb sample), a
plain blue-capped faecal container (for the FC sample) and a
patient instruction sheet to each participant. Patients were
instructed to collect samples from a single faeces for both tests
and to return the samples immediately to the GP surgery. The
samples were returned at room temperature via the GP surgery
routine sample collection service (a daily van courier service) to
Blood Sciences, Ninewells Hospital and Medical School, and
stored at 4°C (FHb) or −20°C (FC) prior to analysis to ensure sta-
bility. FHb measurement was performed using a single
OC-Sensor io analyser (Eiken Chemical Co., Tokyo, Japan).
Inter-run imprecision was assessed with quality control materials
(Eiken) in each run: Co-efficients of Variation (CVs) were 4.6%
at 25 mg/g and 3.9% at 93 mg/g. Any FHb sample that was
reported by the analytical system as a positive numerical result
greater than zero mg/g was considered as a ‘detectable FHb’. FC
was analysed after sample extraction using the Roche device
(Roche Diagnostics, Burgess Hill, UK) using a quantitative ELISA
Calprotectin EK-CAL (BÜHLMANN Laboratories, Switzerland)
on a Dynex DS2 (Alpha Labs, Eastleigh, UK). Inter-run CVs were
5.3% at 37 mg/g and 4.7% at 152 mg/g. Samples with results
above the upper analytical limits were not diluted and re-assayed
but reported as greater than that upper concentration limit. FHb
results were converted from the instrument generated ng/mL to
the internationally recommended unit of mg/g by multiplying by
0.2.20 The laboratory has a total quality management system in
place and is accredited to ISO 15189 based standards. Patients
referred to endoscopy were investigated within 6 weeks of refer-
ral. The endoscopy units participate in the accreditation scheme
of the Joint Accreditation Group on GI Endoscopy. Participating
clinicians and endoscopists were blind to the faecal test results.
All findings were recorded on the endoscopy reporting system by
the endoscopist. The diagnoses of CRC, HRA and IBD were con-
firmed following assessment by a gastrointestinal pathologist.
Clinical outcomes were collected for all patients who completed
the tests, and the diagnostic accuracies of FHb and FC for identi-
fication of significant bowel disease were examined. MedCalc
statistical software (MedCalc Software, Mariakerke, Belgium)
was used for all calculations and to produce distribution plots for
both faecal test results.
RESULTS
In total, 2189 patients were referred for investigation. Also,
1032 (47.1%) referrals were either ‘urgent’ or ‘urgent suspected
cancer’. Of those referred, 1043 patients returned faecal
samples; 12 patients were excluded (seven in whom neither
faecal sample was suitable for analysis, four who returned
samples outside the study period and one patient with known
IBD) leaving 1031 patients (47.1%) who formed the study
cohort (figure 1). The prevalence of referred symptoms within
this cohort was altered bowel habit (42.7%), rectal bleeding
(33.9%), diarrhoea (16.8%), abdominal pain (11.0%), anaemia
(8.7%), weight loss (0.9%) and a palpable mass (0.3%). Eight
patients submitted FHb samples that were spoiled or unsuitable
for analysis. Thirty-nine patients returned FC samples that were
classed as insufficient or unsuitable for analysis. FHb was detect-
able in 57.6% of all samples submitted (median 0.4 mg/g, 95%
CI 0.4 to 0.8; range 0 to >200 mg/g). Using a FHb cut-off of
10 mg/g, the test was positive in 25.2% of samples. FC >50 mg/
g was present in 60.0% of all faecal samples (median 69 mg/g;
range 10 to >600 mg/g).
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A total of 755 patients (54.7% women, median age 64 years
(range 16–90, IQR 52–73)) returned faecal samples and com-
pleted bowel investigations and were included in the analysis of
faecal test performance. The most common findings at colonos-
copy were normal in 241 (33.2%), diverticular disease in 190
(25.2%), haemorrhoids in 98 (13.0%), low-risk adenoma in 65
(8.6%), HRA in 41 (5.4%), IBD in 34 (4.5%) and CRC in 28
patients (3.7%). The PPV of referral symptoms for a diagnosis
of CRC were palpable mass 50.0%, weight loss 14.3%, anaemia
9.0%, rectal bleeding 4.3%, abdominal pain 3.6%, diarrhoea
2.4% and altered bowel habit 2.2%. Rectal bleeding had a PPV
of 21.0% for any significant bowel disease (table 1).
Figures 2 and 3 display the distribution of FHb and FC from
the 1023 and 993 samples, respectively, which were suitable for
analysis. Results are displayed according to the findings of bowel
investigations. In those patients with CRC, the median FHb was
130 mg/g (95% CI 52 to 200, range 0.8 to >200 mg/g). Three
patients with CRC had FHb below 10 mg/g. The prediction of
significant bowel disease was therefore based on the finding of
any detectable FHb.
Faecal test performance
The advantage of using quantitative assays is that cut-off
concentrations that trigger a positive test result can be altered
to regulate positivity rates and diagnostic accuracy (table 2).
Selecting a cut-off of detectable FHb, the positivity rate in
those completing investigations was 58.3%. The PPV for any
significant bowel disease was 20.6%. However, the NPV for
CRC, HRA and IBD were 100%, 97.8% and 98.4%, respect-
ively: 12 of 102 (11.8%) cases of significant bowel disease
had undetectable FHb (seven HRA, five IBD). Interestingly,
256 of the 755 patients described rectal bleeding, but 87
(34.0%) of these had undetectable FHb. In this subgroup,
only 3.4% had significant bowel disease (two with HRA, one
with IBD), and the most common finding was haemorrhoids
(38.0%).
Selecting a FC cut-off of 50 mg/g (often used in differentiating
possible IBD from irritable bowel syndrome), the positivity rate
was 62.0%. The PPV for any significant bowel disease was
16.9% and the PPV for IBD was 6.4%. On the other hand, the
NPV for IBD was 98.9%. However, 25 cases of significant
Figure 1 Study flow diagram. CRC,
colorectal cancer; GP, general
practitioner; HRA, higher-risk
adenoma.
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bowel disease had FC below this cut-off (5 CRC, 17 HRA,
3 IBD).
Selecting a combined cut-off of detectable FHb and/or FC at
50 mg/g generated a high positivity rate of 80.5%. The PPV for
any significant bowel disease was 16.5%. However, only four
cases of significant bowel disease were undetected using this
strategy (three HRA, one IBD).
Raising the FC cut-off to an arbitrary 200 mg/g, the positivity
rate fell to 25.9%, the PPV for IBD increased to 12.2%, yet the
NPV for IBD remained at 98.3%. However, more than half of
the cases of CRC remained undetected.
Selecting a combined cut-off of detectable FHb and/or FC
200 mg/g generated a positivity rate of 66.0%. The PPV for any
significant bowel disease was 18.9%. At this combined cut-off,
the NPV for CRC, HRA, IBD were 100%, 97.6% and 98.8%,
respectively. Nine cases of significant bowel disease were
undetected (six HRA, three IBD).
DISCUSSION
This study demonstrates that patients presenting to primary care
with bowel symptoms can be assessed with faecal tests and the
results can help determine whether further investigation is
Table 1 Symptom prevalence and positive predictive values for colorectal cancer (CRC), higher- risk adenoma (HRA) and IBD in patients
referred from primary care who were investigated for bowel symptoms (n=755)
Total CRC HRA IBD CRC+HRA+IBD
n % n % n % n % n %
Prevalence of symptoms
Altered bowel habit 323 42.8 7 25.0 13 31.7 7 20.6 27 26.2
Rectal bleeding 258 34.2 11 39.3 20 48.8 23 67.6 54 52.4
Diarrhoea 127 16.8 3 10.7 6 14.6 9 26.5 18 17.5
Anaemia 67 8.9 6 21.4 2 4.9 2 5.9 10 9.7
Abdominal pain 83 11.0 3 10.7 5 12.2 2 5.9 10 9.7
Weight loss 7 0.9 1 3.6 0 0.0 0 0.0 1 1.0
Mass 2 0.3 1 3.6 0 0.0 0 0.0 1 1.0
Number of patients 755 28 41 34 103
Positive predictive values
Altered bowel habit 323 42.8 7 2.2 13 4.0 7 2.2 27 8.4
Rectal bleeding 258 34.2 11 4.3 20 7.8 23 8.9 54 21.0
Diarrhoea 127 16.8 3 2.4 6 4.7 9 7.1 18 14.2
Anaemia 67 8.9 6 9.0 2 3.0 2 3.0 10 15.2
Abdominal pain 83 11.0 3 3.6 5 6.0 2 2.4 10 12.0
Weight loss 7 0.9 1 14.3 0 0.0 0 0.0 1 14.3
Mass 2 0.3 1 50.0 0 0.0 0 0.0 1 50.0
Number of patients 755 28 41 34 103
Figure 2 Distribution of faecal
haemoglobin concentration (FHb) in
patient samples collected in primary
care according to the results of bowel
investigations (n=1023). HRA,
higher-risk adenoma
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required. Using detectable FHb as the criterion identified 58.3%
as having a positive test result and gave a PPV of 20.6% for sig-
nificant bowel disease. More importantly, undetectable FHb
effectively ruled out the possibility of underlying CRC and the
possibility of either HRA or IBD was rare. FHb was superior to
FC in this setting; adding in FC at a cut-off of 200 mg/g identi-
fied a further 7.7% with positive tests, but investigation of these
additional patients identified only two further cases of IBD, one
HRA and no additional CRC.
Few studies have assessed the diagnostic accuracy of faecal
tests exclusively within primary care. FC was tested in subjects
aged 18–45 years: a cut-off of 150 mg/g yielded an NPV of 97%
for organic bowel disease but, in this cohort, the prevalence of
CRC was only 0.1%.21 A retrospective population-based study
from Sweden described the impact of a qualitative FIT with an
FHb cut-off of 25 mg/g on the diagnosis of CRC and adenomas
with high-grade dysplasia. A negative test delayed further inves-
tigation and missed about 15% of CRC.22 FHb measured with
a qualitative FIT with a cut-off of 6 mg/g combined with either
qualitative or quantitative FC at a cut-off of 50 mg/g was studied
in 386 patients referred from primary care and gave an NPV of
97.0% for organic bowel disease: this study was limited by
small numbers, studying non-consecutive referrals, inclusion of
diverticulitis within organic bowel disease, and by recruiting
only 19.9% of subjects at the point of referral in primary
care.23 FHb at a cut-off of 20 mg/g was superior to both the
NICE and SIGN guidelines in predicting CRC in 787 symptom-
atic patients referred from primary and secondary care for col-
onoscopy: this was a post hoc analysis of a multicentre study,
the prevalence of CRC was 12.3% and only17.5% were
recruited within primary care.24 Parente and others studied 280
patients awaiting colonoscopy for suspicion of CRC with FHb
at a cut-off equivalent to 20 mg/g on a different FIT quantitative
analytical system (HM-JACK, Kyowa-Medex Co., Tokyo, Japan)
and reported an NPV of 92.0% for CRC plus advanced (higher-
risk) adenoma. Adding FC at 50 mg/g produced an NPV of
94.4%. Those with IBD were excluded.25 A further small study
reported the benefit of a point-of-care qualitative FHb test with
a cut-off of 8 mg/g faeces in the assessment of patients attending
a Rapid Access Clinic in secondary care and, although the
authors concentrated on the use of this as a rule-in test for
CRC, the NPV for CRC was 100%.26
It should be noted that quantitative and qualitative FITanalyt-
ical systems do not give identical results, even if the results are
reported in the recommended units of mg/g:20 this applies to
both qualitative and quantitative FIT.9 27 There are a number of
plausible reasons for this including difference in the mass of
faeces collected, the volume of buffer in the specimen collection
device, the stability of Hb in the device and, probably most
importantly, the specificity of the antibodies used to capture the
Hb and early degradation products for subsequent analysis by
immunochromatography or immunoturbidimetry.28
It is becoming clear from recent studies in CRC screening
programmes that there are marked gender differences; it is well
established that men have a greater prevalence of colorectal neo-
plasia, but it is now also clear that men harbour higher concen-
trations of FHb than women.29 We did not design our study to
examine gender differences; however, we did note a trend for
more significant bowel disease in men (15.5%) versus women
(11.9%). Furthermore, with a cut-off of any detectable FHb,
the PPVs for CRC, HRA plus IBD were higher in men than
women (22.6% vs 18.3%), but there was no difference in
NPVs. While there is a cogent argument to consider gender-
specific FHb cut-offs in asymptomatic population bowel screen-
ing programmes, gender differences in PPV become irrelevant
in a symptomatic patient with detectable FHb because invasive
investigations would be required in all.
The strength of our study is that it was conducted in a single
health care organisation in which all referrals from primary care
enter through a common referral pathway, removing selection
bias. Faecal tests were requested at the point of referral and
samples reached the laboratory via a daily delivery van service.
The mean ambient temperature in this region of Scotland was
never >16°C during the study: therefore, FHb degradation
during transport would be minimal.9 30 The study cohort
appeared to be typical of primary care referrals with 3.7%
Figure 3 Distribution of faecal
calprotectin concentrations in patient
samples collected in primary care
according to the results of bowel
investigations (n=993). HRA,
higher-risk adenoma.
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having underlying CRC, and rectal bleeding having a PPV of
4.3% for CRC.
In population screening and in IBD clinics, FHb and FC
cut-offs have been proposed. With symptomatic patients in
primary care for whom the underlying diagnosis remains to be
determined, we could not anticipate what the appropriate
cut-off concentrations might be. We noted three cases of CRC
in this cohort in whom FHb fell below the 10 mg/g cut-off con-
centration commonly used in CRC screening programmes and
qualitative FIT. In consequence, we chose a cut-off of any
detectable FHb for test performance analysis since no cases of
CRC would be missed. When faced with a symptomatic patient,
an undetectable FHb would reassure a GP that significant bowel
disease would be rare. With FC at the widely used cut-off of
50 mg/g, this proved to be an effective ‘rule-out’ test for IBD,
but would miss almost a fifth of CRC cases. This would not
reassure GPs or patients. If FC is combined with FHb, only one
case of IBD was missed, but the vast majority of patients would
have a positive test (80.5%) and require further investigation.
Raising the FC cut-off to 200 mg/g, combined with detectable
FHb, dropped the combined positivity rate to a manageable
66.0%. However, only three more cases of significant but non-
malignant bowel disease were detected at the expense of investi-
gating 7.7% more referrals than using FHb alone.
At present, in the absence of any reliable predictor of path-
ology, the vast majority of referrals from primary care for
Table 2 Performance of faecal haemoglobin concentration (FHb) and faecal calprotectin concentration (FC) in the detection of colorectal cancer
(CRC), higher-risk adenoma (HRA) and IBD using cut-offs at different concentrations (units: mg/g) (n=755)
FHb ≥10 FC ≥50 FHb detectable
FHb detectable
and/or FC ≥50 FC ≥200
FHb detectable
and/or FC ≥200
Positivity rate 23.5% 62.0% 58.3% 80.5% 25.9% 66.0%
CRC (n=28)
Number of cases 28 28 28 28 28 28
True positives 25 23 28 28 13 28
False negatives 3 5 0 0 15 0
False positives 151 427 409 573 175 464
True negatives 571 271 313 146 523 254
PPV 14.2% 5.1% 6.4% 4.7% 6.9% 5.7%
NPV 99.5% 98.2% 100% 100% 97.2% 100%
Sensitivity 89.3% 82.1% 100% 100% 46.4% 100%
Specificity 79.1% 38.8% 43.4% 20.3% 74.9% 35.4%
HRA (n=41)
Number of cases 40* 41 40 41 41 40
True positives 20 24 33 38 8 34
False negatives 20 17 7 3 33 6
False positives 156 426 404 563 180 458
True negatives 554 259 306 143 505 248
PPV 11.4% 5.3% 7.6% 6.3% 4.3% 6.9%
NPV 96.5% 93.8% 97.8% 97.9% 93.8% 97.6%
Sensitivity 50.0% 58.5% 82.5% 92.7% 19.5% 85.0%
Specificity 78.0% 37.8% 43.1% 20.3% 73.7% 35.1%
IBD (n=34)
Number of cases 34 32* 34 34 32 34
True positives 25 29 29 33 23 31
False negatives 9 3 5 1 9 3
False positives 151 421 408 568 165 461
True negatives 565 273 308 145 529 251
PPV 14.2% 6.4% 6.7% 5.5% 12.2% 6.3%
NPV 98.4% 98.9% 98.4% 99.3% 98.3% 98.8%
Sensitivity 73.5% 90.6% 85.3% 97.1% 71.9% 91.2%
Specificity 78.9% 39.3% 43.0% 20.3% 76.2% 35.3%
CRC+HRA+IBD
Number of cases 102 101* 102 103 101 102
True positives 70 76 90 99 44 93
False negatives 32 25 12 4 57 9
False positives 106 374 347 502 144 399
True negatives 542 251 301 142 481 245
PPV 39.8% 16.9% 20.6% 16.5% 23.4% 18.9%
NPV 94.4% 90.9% 96.2% 97.3% 89.4% 96.5%
Sensitivity 68.6% 75.2% 88.2% 96.1% 43.6% 91.2%
Specificity 83.6% 40.2% 46.4% 22.0% 77.0% 38.0%
*One case of HRA had FHb sample unsuitable for analysis. Two cases of IBD had FC samples unsuitable for analysis.
NPV, negative predictive value.
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assessment of colorectal symptoms undergo invasive investiga-
tions but the yield of pathology is low. This study demonstrates
that FHb and FC can provide objective information on the like-
lihood of significant underlying pathology but cannot replace
common sense. Patients with anaemia or a mass require investi-
gation irrespective of faecal test results. However, 34.0% with
rectal bleeding had undetectable FHb; upon investigation hae-
morrhoids were the most common finding and the incidence of
significant bowel disease was only 3.4%. Based on our findings,
patients presenting to primary care with bowel symptoms could
be tested with FHb and FC in the knowledge that approxi-
mately one-third of patients who would normally be referred
for investigation will have negative test results and do not
require immediate invasive investigations. In our health care
organisation, this translates into almost 1200 patients per year
who are highly likely to have no significant bowel disease and
do not require immediate investigation. If FHb was the sole
faecal test, that figure would rise to almost 1400. Moreover,
using one only test has advantages since FIT specimen collection
devices are more user-friendly, FHb is cheaper to analyse and
has a more rapid turnaround time.
In summary, this study demonstrates that non-invasive faecal
tests requested in primary care provide a reliable prediction of
the absence of significant bowel disease. FHb is superior to FC
and enables, with a single faecal test, an objective assessment of
the need and urgency of further investigation.
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